Loading…
Loading…
The Invesco Nasdaq Biotechnology ETF (IBBQ) seeks to mirror the investment performance of the Nasdaq Biotechnology Index. To achieve this, the Fund generally dedicates at least 90% of its total capital to the securities that make up this benchmark index. The underlying Index itself is specifically designed to gauge the returns of biotechnology and pharmaceutical companies whose shares are publicly traded on the Nasdaq Stock Market. Both the ETF and its corresponding Index undergo a yearly review and update of their composition each December, and their weightings are adjusted quarterly in March, June, September, and December.
Is IBBQ's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
The Invesco Nasdaq Biotechnology ETF (IBBQ) carries a lower expense ratio than the iShares Global Healthcare ETF (IXJ). IXJ offers broad global exposure across the healthcare sector, while IBBQ is concentrated exclusively in Nasdaq-listed biotechnology and pharmaceutical companies.
State Street Health Care Select Sector SPDR ETF offers a lower expense ratio and a higher dividend yield than Invesco Nasdaq Biotechnology ETF Invesco Nasdaq Biotechnology ETF provides concentrated exposure to the biotech industry but has experienced higher volatility and a deeper maximum drawdown State Street Health Care Select Sector SPDR ETF tracks a broader index of 60 healthcare stocks from the S&P 500 compared to the Invesco fund's 253 biotech holdings
Invesco Nasdaq Biotechnology ETF offers a lower expense ratio and a higher trailing dividend yield than State Street SPDR S&P Pharmaceuticals ETF. State Street SPDR S&P Pharmaceuticals ETF has delivered a higher 1-year total return and experienced a less severe maximum drawdown than Invesco Nasdaq Biotechnology ETF.
Compare diversification strategies and see how each ETF's unique index focus shapes risk and return for healthcare sector investors.
Invesco Nasdaq Biotechnology ETF (NASDAQ: IBBQ - Get Free Report) saw a significant increase in short interest during the month of January. As of January 15th, there was short interest totaling 23,534 shares, an increase of 202.1% from the December 31st total of 7,789 shares. Approximately 0.9% of the shares of the stock are short sold.